retatrutide weight loss phase 2 trial results There is a new shot moving through trials and the numbers are bigger than anything we have seen. It is called Retatrutide. At the highest dose people lost 30 percent A New Obesity Drug Delivered

In the ATTAIN-1 trial, participants achieved a mean weight loss of 12.4% over 72 weeks. Foundayo is not yet approved or available in the UK

BPC-157 is being studied for its potential anti-inflammatory properties, which may help support comfort and recovery

Jeong H-K, Jou I

GCGR activation, represented in green, is unique in that glucagon receptors are robustly expressed on hepatocytes, enabling direct liver-directed metabolic effects - a mechanistic feature absent from both GLP-1R and GIPR signaling

During the treatment, glutathione is administered intravenously under the supervision of a qualified healthcare professional like Dr